BioSpace News Archive

HOOKIPA Pharma Inc., a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced positive Phase 1 results from its HB-200 program evaluating single-vector HB-201 and alternating 2-vector HB-202/HB-201 in advanced Human Papillomavirus 16-positive head and neck cancer patients.

Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference of 7.9%,1 making it the first and only 14-day continuous glucose monitoring system to achieve a sub-8% overall MARD.

Eisai announced new investigational data from the platinum-resistant ovarian cancer cohort expansion of a Phase 1 study evaluating the antibody drug conjugate co-developed by Eisai and Bristol Myers Squibb, farletuzumab ecteribulin.

NANOBIOTIX announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology featuring potential first-in-class radioenhancer NBTXR3 in combination with concurrent chemoradiation for the treatment of head and neck cancer and rectal cancer.

Agendia, Inc. announced it will present seven posters derived from the company’s FLEX Trial, the real-world, multicenter, prospective, observational breast cancer study at the American Society of Clinical Oncology Annual Meeting 2022.

Merus N.V. announced interim efficacy data as of an April 12, 2022 data cutoff date, from the phase 1/2 eNRGy trial and Early Access Program of the bispecific antibody Zeno in patients with NRG1+ cancer presented virtually by Lead Author, Dr. Alison Schram of Memorial Sloan Kettering Cancer Center at the 2022 ASCO Annual meeting.

Lytix Biopharma AS, a clinical-stage company with an in situ vaccination technology platform, announces data from its ATLAS-IT-04 trial in patients with progressive metastatic soft tissue sarcoma.

BioNTech SE announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability of the mRNA-based individualized neoantigen specific immunotherapy autogene cevumeran in combination with anti-PD-L1 immune checkpoint inhibitor atezolizumab and chemotherapy in patients with resected pancreatic ductal adenocarcinoma.

Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions.

Two analyses of the final U.S. data from the EMPagliflozin compaRative effectIveness and SafEty real-world study show that Jardiance® was associated with a reduction in risk of hospitalization for heart failure compared with two other classes of glucose-lowering therapies in adults with type 2 diabetes in routine care.